• Questions? +1 (732) 747-1007
  • ir@americancryostem.com
  • Physicians
  • Licensing & Partners
American CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell TherapyAmerican CryoStem, Stem Cell Therapy
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT
    • ADULT STEM CELLS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • OUR SCIENCE
    • LONG COVID CLINICAL TRIAL
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT

ATGRAFT Tissue Storage Featured in MedEsthetics

October 2, 2014

Leading medical publication MedEsthetics interviewed Dr. Fredric Stern in a featured article on “Autologous fillers and topicals” in their September 2014 issue.

MedAutologousMedicine914-1An excerpt from the article Dr. Stern discusses the benefits of layered fat transfer using cryopreserved tissue.

One advancement that may make fat transfer a more viable option for long-term filler patients who want permanent improvement—but do not plan to undergo facelift or liposuction—is cryopreservation of fat. This technique allows the physician to harvest fat once and preserve it for future injections, which are offered over the course of several months.

Dr. Stern has found that offering a one-time “mini-lipo” harvesting procedure with cryopreservation is an attractive option for patients interested in replacing dermal fillers with fat transfer.

“If you look at patients who have had fat transfer versus fillers, the patients getting autologous fat injections look better,” he says. “They’re not just filled, the appearance of the skin is improved. It looks healthier, as if they’re building their own collagen.”

To read the complete featured article click here

Share

Related posts

January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)


Read more
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board


Read more
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)


Read more

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), is a clinical-stage biotechnology company, global licensor and a pioneer in autologous (one’s own) cellular processing and therapies. The Company's centralized laboratory model and patented foundational “CryoStem Platform” is a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders and chronic diseases through a single adipose-tissue (fat) harvest and ATCELLBank™ cryopreservation. We are dedicated to helping the world’s physicians, hospitals, and clinics improve clinical outcomes by developing and delivering effective leading-edge stem cell therapies that improve patient health and quality of life.

© 2021 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners